Quick Answer
Insight Molecular Diagnostics Inc. reported Cash and Equivalents of $11.58 million for fiscal year 2025.
Insight Molecular Diagnostics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $11.58M | +34.1% |
| 2024 | $8.64M | -8.4% |
| 2023 | $9.43M | -52.8% |
| 2022 | $19.99M | -39.3% |
| 2021 | $32.95M | +361.3% |
| 2020 | $7.14M | -67.6% |
| 2019 | $22.07M | +174.7% |
| 2018 | $8.03M | +5.7% |
| 2017 | $7.60M | -25.3% |
| 2016 | $10.17M | +27.2% |
| 2015 | $8.00M | +3011.3% |
| 2014 | $257.0K | +154.5% |
| 2013 | $101.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $18.69M | +455.8% | -23.0% |
| June 30, 2025 | $24.29M | +162.4% | -21.7% |
| March 31, 2025 | $31.03M | +456.3% | +259.3% |
| December 31, 2024 | $8.64M | -8.4% | +156.8% |
| September 30, 2024 | $3.36M | -75.6% | -63.7% |
| June 30, 2024 | $9.26M | -46.7% | +65.9% |
| March 31, 2024 | $5.58M | -52.7% | -40.9% |
| December 31, 2023 | $9.43M | -52.8% | -31.6% |
- Insight Molecular Diagnostics Inc. showed an increase of +34.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2025 period, Insight Molecular Diagnostics Inc.’s cash and equivalents has grown by 11368.3% (from $101.0 thousand to $11.58 million).
- The most recent figure is from Insight Molecular Diagnostics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: